Literature DB >> 16229165

Mixed opioid/nonopioid effects of dynorphin and dynorphin related peptides after their intrathecal injection in rats.

R Przewłocki1, G T Shearman, A Herz.   

Abstract

Dynorphin dose-dependently increased the tail flick latency of rats to radiant heat following its intrathecal injection. This effect was accompanied by an alteration in motor function that was characterized by a flaccid extension of the hindlimbs and flaccidity of the tail. Naloxone (10 but not 1 mg/kg) blocked the antinociceptive effect and motor disturbance produced by dynorphin. The non-opioid analogue des-Tyr1-dynorphin(1-13) also increased tail flick latency and produced paralysis. Dynorphin(1-8) significantly elevated tail flick latency without affecting motor function. Furthermore, the effect of dynorphin(1-8) was blocked by 1 mg/kg naloxone. These data suggest a possible physiological role of dynorphin in influencing motor function in the spinal cord and a role of dynorphin(1-8) in modulating pain transmission. Another finding of the present study was that dynorphin was approximately ten times more potent in producing its effects when injected one day after surgery compared to when it when it was injected one week or more after surgery.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 16229165     DOI: 10.1016/0143-4179(83)90019-7

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  14 in total

1.  On the selectivity of intravenous mu- and kappa-opioids between nociceptive and non-nociceptive reflexes in the spinalized rat.

Authors:  C G Parsons; P M Headley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

Review 2.  Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides.

Authors:  V K Shukla; S Lemaire
Journal:  J Psychiatry Neurosci       Date:  1992-09       Impact factor: 6.186

Review 3.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

Review 4.  Spinal opioid systems in inflammation.

Authors:  L Stanfa; A Dickenson
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

5.  Spinal antinociceptive actions of mu- and kappa-opioids: the importance of stimulus intensity in determining 'selectivity' between reflexes to different modalities of noxious stimulus.

Authors:  C G Parsons; P M Headley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

6.  Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation.

Authors:  I Obara; J Mika; M K-H Schafer; B Przewlocka
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

7.  Generalization tests with intraventricularly applied pro-enkephalin B-derived peptides in rats trained to discriminate the opioid kappa receptor agonist ethylketocyclazocine.

Authors:  G T Shearman; R Schulz; P W Schiller; A Herz
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action.

Authors:  A I Faden; T P Jacobs
Journal:  Br J Pharmacol       Date:  1984-02       Impact factor: 8.739

Review 9.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective.

Authors:  Sonia Podvin; Tony Yaksh; Vivian Hook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

10.  Effects of acute agonist treatment on subcellular distribution of kappa opioid receptor in rat spinal cord.

Authors:  Yulin Wang; Wei Xu; Peng Huang; Charles Chavkin; Elisabeth J Van Bockstaele; Lee-Yuan Liu-Chen
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.